+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Risk factors and clinical outcomes of pediatric liver transplant recipients with post-transplant lymphoproliferative disease in a multi-ethnic Asian cohort



Risk factors and clinical outcomes of pediatric liver transplant recipients with post-transplant lymphoproliferative disease in a multi-ethnic Asian cohort



Transplant Infectious Disease 20(1):



We aimed to evaluate clinical characteristics, risk factors, and disease outcomes for liver transplant recipients (LTR) with post-transplant lymphoproliferative disease (PTLD) at our center. Retrospective review of data of all pediatric LTR (1991-2015) was conducted. The overall incidence of PTLD was 16.4% (18/110), the majority (13/18) were early lesions, while 3/18 were polymorphic/monomorphic PTLD. The risk factors significant on univariate analysis were as follows: mean age (years) at transplant (1.66 vs 4.76, P = .006); age <2 years at transplant (odds ratio [OR] 3.53 [95% confidence interval [CI]: 1.16-10.73], P = .026); cytomegalovirus (CMV) primary infection (OR 11.39 [95% CI: 3.44-37.7], P < .001); recipient CMV seronegativity (OR 7.50 [95% CI: 2.02-27.78], P = .003); presence of CMV end-organ disease (OR 4.00 [95% CI: 1.22-13.16], P = .022); Chinese ethnicity; and higher mean duration of intravenous ganciclovir prophylaxis. In multivariate analysis, CMV primary infection (OR 5.22 [95% CI: 1.25-21.87], P = .024), CMV seronegativity (OR 5.91 [95% CI: 1.13-30.90, P = .035]), and having acute cellular rejections (ACR) prior to PTLD (OR 5.53 [95% CI: 1.43-21.48, P = .013]) were significant risk factors for PTLD, with the latter two factors having a synergistic effect in increasing PTLD risk in a stratified analysis. The final multivariate model in predicting the risk of PTLD, utilizing CMV primary infection, recipient CMV seronegativity, and ACR before PTLD as predictive variables, was statistically significant (likelihood ratio chi square statistic = 25.18, P < .0001 with df = 3). We report a unique clinicopathologic and risk factor profile in our cohort-early lesion PTLD accounts for the majority and the incidence of monomorphic PTLD remains low. In addition, we show a synergism between CMV naivety and ACR on PTLD risk, a higher prevalence of gastrointestinal manifestations, and a lack of significant association with Epstein-Barr virus seronegativity.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 060210086

Download citation: RISBibTeXText

PMID: 29071779

DOI: 10.1111/tid.12798


Related references

Analysis of risk factors for post-transplant lymphoproliferative disease in pediatric lung transplant recipients with cystic fibrosis. Pediatric Research 43(4 Part 2): 131A, 1998

Primary tacrolimus (FK506) therapy and the long-term risk of post-transplant lymphoproliferative disease in pediatric liver transplant recipients. Pediatric Transplantation 5(5): 359-364, 2001

The use of objective case ascertainment to identify risk factors for Epstein-Barr virus-associated post-transplant lymphoproliferative disorder in pediatric liver transplant recipients. Hepatology 36(4 Part 2): 662A, 2002

Case-control study of risk factors for the development of post-transplant lymphoproliferative disease in a pediatric heart transplant cohort. Pediatric Transplantation 11(1): 58-65, 2007

Sirolimus for pediatric liver transplant recipients with post-transplant lymphoproliferative disease and hepatoblastoma. Pediatric Transplantation 8(3): 243-248, 2004

Incidence and risk factors of EBV related post transplant lymphoproliferative diseases in paediatric liver transplant recipients treated with tacrolimus. Hepatology 26(4 Part 2): 343A, 1997

Risk factors that influence survival in kidney transplant recipients with post-transplant lymphoproliferative disease A multivariate analysis. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 178A, 2002

Factors associated with the development of post-transplant lymphoproliferative disease (PTLD) in Epstein-Barr virus (EBV)-seronegative adult liver transplant recipients. Transplant International 7(Suppl. 1): S235-S237, 1994

Factors associated with the development of post-transplant lymphoproliferative disease (PTLD) in Epstein-Barr virus (EBV) - seronegative adult liver transplant recipients. Transplant International 7(Suppl. S1): 235-237, 1994

Plasmacytoma-like post-transplant lymphoproliferative disorder seen in pediatric combined liver and intestinal transplant recipients. Pediatric Blood and Cancer 60(11): E137-E139, 2013

Non-adherence to post-transplant care: prevalence, risk factors and outcomes in adolescent liver transplant recipients. Pediatric Transplantation 12(2): 194-200, 2008

Posttransplant biopsy risk for stable long-term pediatric liver transplant recipients: 451 percutaneous biopsies from two multicenter immunosuppression withdrawal trials. American Journal of Transplantation 19(5): 1545-1551, 2019

Epstein-Barr viral loads do not predict post-transplant lymphoproliferative disorder in pediatric lung transplant recipients: A multicenter prospective cohort study. Pediatric Transplantation 21(6):, 2017

Post-transplant lymphoproliferative disease in pediatric solid organ transplant recipients. Pediatric Hematology and Oncology 30(6): 520-531, 2013

Post transplant lymphoproliferative disease in pediatric lung transplant recipients. Journal of Heart & Lung Transplantation 17(1): 65, 1998